FDA Grants Priority Review to Jazz Pharmaceuticals' Gastric Cancer Drug

The U.S. FDA has accepted a supplemental Biologics License Application for Jazz Pharmaceuticals' Ziihera (zanidatamab-hrii) combinations. The application, which received Priority Review, seeks approval for the first-line treatment of specific HER2-positive gastric cancers. A decision from the FDA is anticipated by August 25, 2026.

Context

HER2-positive gastric cancer is a subtype that tends to be more aggressive and has fewer effective treatments available. Jazz Pharmaceuticals is seeking to expand the use of Ziihera, which is already under investigation for its efficacy in this specific cancer type. The FDA's acceptance of the application indicates a recognition of the drug's potential benefits.

Why it matters

The FDA's Priority Review designation highlights the potential significance of Ziihera in treating HER2-positive gastric cancers, a condition with limited treatment options. This could lead to improved patient outcomes and provide new hope for those affected by this aggressive cancer type. The decision will also impact the competitive landscape of cancer therapies.

Implications

If approved, Ziihera could become a standard treatment option for patients with HER2-positive gastric cancer, potentially changing treatment protocols. This may also influence the market dynamics for cancer therapies, prompting other companies to accelerate their research and development efforts in this area. Patients, healthcare providers, and insurers will all be affected by the availability and cost of this new treatment.

What to watch

The FDA is expected to make a decision on the application by August 25, 2026. Stakeholders will be monitoring the review process closely for any updates or indications of the FDA's stance on the drug's safety and efficacy. Additionally, the response from the medical community and patient advocacy groups will be important.